{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:52:35Z","timestamp":1781679155477,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite ongoing global efforts, drug-resistant TB (DR-TB) continues to pose a substantial threat to public health, and systematic longitudinal surveillance data on local resistance patterns are lacking in many regions. This study analyzed first-line drug resistance patterns and annual trends in Lishui, China from 2015 to 2024 and identified independent risk factors for multidrug-resistant tuberculosis (MDR-TB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 2,339\u202fTB patients with available phenotypic drug susceptibility testing (pDST) results from the designated TB treatment institution in Lishui were retrospectively enrolled between January 2015 and December 2024. Annual drug resistance trends were assessed, and independent risk factors for MDR-TB were evaluated through multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall prevalence of DR-TB and MDR-TB was 20.09 and 6.93%, respectively. Over the 10-year period, overall DR-TB prevalence declined from 23.50% in 2015 to 15.63% in 2024 (APC: \u22121.30%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.661), with this reduction largely attributable to the declining trend among retreated patients (56.25\u201315.00%, APC: \u22128.19%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.156), while resistance rates in new patients remained broadly stable (APC: +0.95%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.732). MDR-TB prevalence in retreated patients decreased significantly from 40.63 to 15.00% (Cochran-Armitage trend test,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.008). Prior TB treatment history (AOR\u202f=\u202f4.345, 95% CI: 3.029\u20136.234,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and farmer occupation (AOR\u202f=\u202f1.638, 95% CI: 1.047\u20132.562,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.031) were identified as independent risk factors for MDR-TB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The decrease in drug resistance among retreated patients was the main driver of the overall decline in DR-TB prevalence observed in Lishui across the study period. The relative stability of resistance in new patients suggests ongoing circulation of drug-resistant strains in the community, highlighting the need for expanded drug susceptibility testing (DST) coverage and strengthened community infection control. Enhanced treatment adherence and universal pDST coverage, particularly for retreated patients and socioeconomically vulnerable populations such as farmers, are essential for effective MDR-TB containment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1855459","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:57:19Z","timestamp":1781675839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-resistant tuberculosis in Lishui, China: first-line drug resistance patterns, trends, and risk factors from a 10-year retrospective study (2015\u20132024)"],"prefix":"10.3389","volume":"14","author":[{"given":"Honghui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjuan","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Lishui Traditional Chinese Medicine Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref1","volume-title":"Global Tuberculosis Report","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"937844","DOI":"10.3389\/fpubh.2022.937844","article-title":"Influence of COVID-19 for delaying the diagnosis and treatment of pulmonary tuberculosis-Tianjin, China","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1186\/s12879-025-11566-2","article-title":"Global burden of MDR-TB and XDR-TB: trends, inequities, and future implications for public health planning","volume":"25","author":"Tan","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1550199","DOI":"10.3389\/fpubh.2025.1550199","article-title":"Trends and forecast of drug-resistant tuberculosis: a global perspective from the GBD study 2021","volume":"13","author":"Guo","year":"2025","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1369541","DOI":"10.3389\/fpubh.2024.1369541","article-title":"Analysis of care-seeking and diagnosis delay among pulmonary tuberculosis patients in Beijing, China","volume":"12","author":"Zhang","year":"2024","journal-title":"Front Public Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"943545","DOI":"10.3389\/fcimb.2022.943545","article-title":"Drug resistant tuberculosis: implications for transmission, diagnosis, and disease management","volume":"12","author":"Liebenberg","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","article-title":"Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis","volume":"17","author":"Xi","year":"2022","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/IDR.S436563","article-title":"Trends of drug-resistant tuberculosis in an urban and a rural area in China: a 10-year population-based molecular epidemiological study","volume":"17","author":"Xu","year":"2024","journal-title":"Infect Drug Resist"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.2147\/IDR.S373125","article-title":"Drug resistance patterns and trends in patients with suspected drug-resistant tuberculosis in Dalian, China: a retrospective study","volume":"15","author":"Pan","year":"2022","journal-title":"Infect Drug Resist"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1611322","DOI":"10.3389\/fmed.2025.1611322","article-title":"Drug resistance patterns, trends, and risk factors for multidrug resistance of tuberculosis in Wenzhou, China: a ten-year retrospective analysis (2014-2023)","volume":"12","author":"Wu","year":"2025","journal-title":"Front Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13756-018-0348-7","article-title":"Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China","volume":"7","author":"Li","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1047659","DOI":"10.3389\/fpubh.2022.1047659","article-title":"Drug resistance patterns and dynamics of tuberculosis in Zhejiang Province, China: results from five periodic longitudinal surveys","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","unstructured":"China\u2019s National TB Prevention and Control Technical Work Regulations (2020 Edition). Beijing: National Health Commission of the People\u2019s Republic of China\n          \n          \n          \n          2020"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jgar.2024.05.018","article-title":"Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China: a systematic review and meta-analysis","volume":"38","author":"Jin","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-8-166","article-title":"Prevalence of tuberculosis drug resistance in 10 provinces of China","volume":"8","author":"He","year":"2008","journal-title":"BMC Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.52225\/narra.v3i2.220","article-title":"Risk factors of MDR-TB and impacts of COVID-19 pandemic on escalating of MDR-TB incidence in lower-middle-income countries: a scoping review","volume":"3","author":"Ichsan","year":"2023","journal-title":"Narra J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(16)30418-2","article-title":"Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation","volume":"17","author":"Yang","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2348505","DOI":"10.1080\/22221751.2024.2348505","article-title":"Transmission characteristics in tuberculosis by WGS: nationwide cross-sectional surveillance in China","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/phn.12582","article-title":"Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis","volume":"36","author":"Feng","year":"2019","journal-title":"Public Health Nurs"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e001999","DOI":"10.1136\/bmjresp-2023-001999","article-title":"Determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray region, Ethiopia: a case-control study","volume":"11","author":"Zereabruk","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1410690","DOI":"10.3389\/fmed.2024.1410690","article-title":"Risk factors for multidrug-resistant tuberculosis: a predictive model study","volume":"11","author":"Wu","year":"2024","journal-title":"Front Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1117101","DOI":"10.3389\/fpubh.2023.1117101","article-title":"Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China","volume":"11","author":"Wang","year":"2023","journal-title":"Front Public Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1855459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:57:21Z","timestamp":1781675841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1855459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":23,"alternative-id":["10.3389\/fpubh.2026.1855459"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1855459","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1855459"}}